What does it mean when liver enzymes stay elevated?
Understanding the path from abnormal labs to Hepatitis C diagnosis and modern curative treatment
Your guardians. GastroDoxs GutGuardians™ is an elite team of board-certified gastroenterologists - a physician-led defense force of specialists, systems, and solution pathways working together to protect, detect, solve, and defend your digestive health through expert GI evaluation, advanced diagnostic screening, and endoscopic evaluation - commanded from your first concern to your last follow-up, and every critical stage in between.
When routine blood work reveals more than expected
Caleb had always considered himself healthy. At 52, he managed a busy career, stayed active on weekends, and rarely thought about his health beyond annual checkups. When his primary care doctor ordered routine blood work during his physical, he expected everything to come back normal.
The call came three days later. His liver enzymes were elevated—ALT at 78 and AST at 65, both well above the normal range. His doctor mentioned it could be many things: fatty liver, medication effects, or perhaps something viral. She recommended repeating the labs in six weeks.
Caleb felt confused. He didn't drink heavily, took no regular medications, and felt fine. The numbers meant nothing to him. He had a major project deadline at work, and the idea of more medical appointments felt overwhelming. He told himself he'd follow up after things calmed down.
I thought elevated liver enzymes were just a fluke. I didn't realize they were trying to tell me something important.
Looking back, Caleb realized there had been signs. For the past year, he'd felt more tired than usual. He chalked it up to stress and getting older. Some afternoons, he'd struggle to focus during meetings, his mind feeling foggy. He'd started drinking more coffee to compensate.
Occasionally, he noticed a dull ache in his upper right abdomen, just below his ribs. It wasn't sharp or constant—more like a vague heaviness that came and went. He assumed it was indigestion or muscle strain from yard work.
His wife mentioned he seemed more irritable lately. Small frustrations that wouldn't have bothered him before now felt overwhelming. He attributed it to work pressure and didn't connect it to anything physical.
Three months passed before Caleb's trigger moment arrived—a combination of worsening symptoms and undeniable lab results that demanded attention.
Caleb finally repeated his blood work in late fall, nearly four months after the initial abnormal results. His primary care doctor called the same day the results came in. His liver enzymes had climbed higher: ALT now 92, AST 78. His doctor's tone was different this time—more serious, more urgent.
She explained that persistently elevated enzymes suggested ongoing liver inflammation. She ordered additional tests: a Hepatitis C antibody screen, hepatitis B panel, and liver ultrasound. The word 'hepatitis' caught Caleb off guard. He associated that with something serious, something that required real medical attention.
The Hepatitis C antibody came back positive. His doctor explained this meant he'd been exposed to the virus at some point, but they needed a viral load test to confirm active infection. She referred him to a gastroenterologist who specialized in liver disease. Suddenly, this wasn't just confusing numbers on a lab report—it was a diagnosis.
Caleb sat in his car after the appointment, staring at the referral paperwork. He thought about his kids, his retirement plans, the life he'd assumed stretched out predictably ahead. The fatigue he'd been ignoring suddenly felt ominous. The vague abdominal discomfort took on new meaning. He couldn't delay anymore.
Facing a Hepatitis C diagnosis, Caleb recognized he needed specialized knowledge to understand his condition and treatment options.
Caleb spent the evening reading about Hepatitis C. He learned that modern treatments had revolutionized outcomes—cure rates above 95%, short treatment courses, minimal side effects. This was vastly different from the interferon-based therapies he vaguely remembered hearing about years ago. The information was both reassuring and overwhelming. He needed expert guidance to navigate his specific situation.
His primary care doctor had been clear: managing Hepatitis C required specialized expertise. A hepatologist could assess his liver damage stage, determine the specific viral genotype, evaluate treatment options, and monitor for complications. This wasn't something to manage through routine primary care visits. He needed someone who treated liver disease every day.
Caleb called the gastroenterology practice his doctor recommended. The scheduler explained they'd need his recent lab results, imaging reports, and insurance information. She mentioned the hepatologist would likely order additional testing to fully stage his disease before recommending treatment. The first available appointment was in two weeks. Caleb took it, feeling both anxious and relieved to have a concrete next step.
Before his appointment, Caleb wrote down questions: How did I get this? How long have I had it? How much liver damage has occurred? What are my treatment options? What happens if I don't treat it? He gathered his medical records and made a list of all medications and supplements. He wanted to use the consultation time efficiently and understand his situation completely.
Early evaluation of elevated liver enzymes can detect treatable conditions before they progress. Our hepatology specialists provide comprehensive liver health assessment and evidence-based treatment.
Hepatitis C typically progresses silently over years or decades. Understanding this timeline helps explain why early detection through screening is critical.
Initial viral exposure may cause mild flu-like symptoms or remain completely asymptomatic. About 15-25% of people clear the virus naturally during this phase. Most develop chronic infection without realizing they were exposed.
The virus replicates steadily while the immune system causes ongoing liver inflammation. Most people feel completely normal. Liver enzymes may fluctuate between normal and mildly elevated. This is when screening often detects the infection.
Repeated inflammation causes scar tissue formation (fibrosis). Liver function remains adequate, but structural changes begin. Fatigue, brain fog, and mild abdominal discomfort may emerge. Liver enzymes become persistently elevated.
Without treatment, 20-30% of chronic infections progress to cirrhosis. Risk of liver cancer increases significantly. Symptoms become more pronounced: jaundice, fluid retention, confusion, bleeding tendency. This stage requires urgent intervention.
Hepatitis C often presents through routine screening or incidental findings. Recognizing these entry points enables early intervention before significant liver damage occurs.
ALT or AST levels remain above normal range on repeat testing over 3-6 months without clear alternative cause
History of blood transfusion before 1992, injection drug use, tattoos from unregulated facilities, or healthcare exposure
One-time screening recommended for all adults born between 1945-1965 due to higher prevalence rates
Persistent low energy, brain fog, or malaise without clear explanation, especially with other liver-related symptoms
Liver texture changes, mild enlargement, or fatty infiltration noted on ultrasound or CT performed for other reasons
The CDC recommends universal Hepatitis C screening for all adults at least once in their lifetime. Early detection prevents progression to cirrhosis and enables curative treatment.
Hepatitis C represents a curable chronic viral infection that requires systematic evaluation and evidence-based treatment. Modern hepatology approaches this condition with precision diagnostics and highly effective antiviral therapy.
Hepatitis C virus spreads through blood-to-blood contact. Historical risk factors include blood transfusions before 1992, injection drug use, tattoos from unregulated facilities, and certain medical procedures. Many patients cannot identify a specific exposure event. The virus establishes chronic infection in 75-85% of exposed individuals, causing progressive liver inflammation over decades if untreated.
Initial screening uses HCV antibody testing, which indicates past or present exposure. Positive antibody tests require HCV RNA viral load confirmation to distinguish active infection from cleared past infection. Genotype testing guides treatment selection. Liver fibrosis staging through elastography or biopsy determines urgency and prognosis. Baseline labs assess liver function and rule out co-infections.
Fibrosis progression varies widely between individuals. Factors accelerating progression include alcohol use, obesity, diabetes, and co-infection with HIV or hepatitis B. Cirrhosis develops in 20-30% of untreated patients over 20-30 years. Once cirrhosis develops, annual liver cancer risk reaches 2-4%. Early-stage disease has excellent prognosis with treatment, while advanced cirrhosis requires ongoing surveillance even after viral cure.
Direct-acting antiviral (DAA) medications target specific viral proteins, achieving cure rates above 95% with 8-12 weeks of oral therapy. Treatment is well-tolerated with minimal side effects. Regimen selection depends on genotype, prior treatment history, and cirrhosis presence. Successful treatment eliminates the virus permanently, halts fibrosis progression, and reduces cancer risk, though cirrhosis surveillance continues if advanced disease was present.
Sustained virologic response (SVR)—undetectable virus 12 weeks after treatment completion—indicates cure. Patients with minimal fibrosis require no ongoing monitoring after achieving SVR. Those with advanced fibrosis or cirrhosis need continued surveillance for liver cancer and varices even after cure. Lifestyle modifications addressing metabolic factors optimize long-term liver health.
Caleb's first hepatology visit provided comprehensive assessment of his liver health and clear treatment planning.
The hepatologist spent significant time reviewing Caleb's history. They discussed potential exposure sources: Caleb recalled receiving a blood transfusion after a car accident in 1989, well before routine screening began. The doctor explained this was a common exposure route for his age group. They reviewed his alcohol intake, medications, family history, and symptoms. The thoroughness helped Caleb understand his disease wasn't his fault—it was an unfortunate exposure decades ago.
The physical exam focused on signs of liver disease. The doctor palpated Caleb's abdomen, checking for liver enlargement or tenderness. She examined his skin for spider angiomas or jaundice, checked for fluid retention in his legs, and assessed for signs of advanced disease. Everything appeared reassuringly normal. The doctor explained that early-stage hepatitis C rarely causes physical exam abnormalities—another reason why screening is so important.
The hepatologist pulled up Caleb's labs on the computer screen and walked through each result. His HCV RNA viral load was 2.4 million IU/mL—confirming active infection. Genotype testing showed type 1a, the most common strain in the United States. His liver function tests showed elevated enzymes but normal synthetic function—his liver was inflamed but still working well. Platelet count and other markers suggested minimal fibrosis.
The doctor ordered a FibroScan—a non-invasive ultrasound-based test measuring liver stiffness. The test took about 10 minutes and was completely painless. Results showed F1 fibrosis (mild scarring) with no evidence of cirrhosis. The hepatologist explained this was excellent news: his liver had sustained minimal damage despite years of infection. Treatment would prevent any further progression and likely allow some fibrosis regression.
Based on his genotype and fibrosis stage, the doctor recommended an 8-week course of direct-acting antivirals. She explained the medication mechanism, expected cure rate (over 97% for his profile), and minimal side effects. They discussed insurance authorization, medication costs, and monitoring schedule. Caleb would need labs at week 4 of treatment and 12 weeks after completion to confirm cure. The simplicity and effectiveness surprised him—this was far easier than he'd feared.
Modern Hepatitis C treatment follows a straightforward protocol with high success rates and minimal disruption to daily life.
The practice's specialty pharmacy coordinator handled insurance authorization. Caleb's plan required documentation of his fibrosis stage and viral load. Approval came within a week. The coordinator explained patient assistance programs that reduced his copay to $50 per month. The medication arrived at his home in discreet packaging with clear instructions and a treatment calendar.
Caleb began his medication on a Monday morning—one pill, once daily, taken with food. The hepatologist had warned about potential fatigue or headache, but Caleb experienced neither. He set a daily phone alarm to ensure consistent timing. The treatment calendar helped him track each day. He continued working normally, exercising, and maintaining his routine. The ease of treatment felt almost anticlimactic after months of worry.
At week 4, Caleb returned for follow-up labs. His viral load had dropped to undetectable—exactly what the doctor hoped to see. His liver enzymes had already begun normalizing: ALT down to 45, AST to 38. The hepatologist was pleased with his response. They discussed the importance of completing the full 8-week course even though the virus was undetectable. Caleb felt encouraged by the tangible progress.
Caleb took his final pill on a Friday evening, marking the date on his calendar. He'd experienced no significant side effects throughout the course. His energy had actually improved—he wasn't sure if this was psychological or physiological, but he felt more like himself than he had in years. The hepatologist scheduled his SVR12 test (sustained virologic response at 12 weeks post-treatment) for three months out.
Twelve weeks after finishing treatment, Caleb's HCV RNA remained undetectable. His liver enzymes had normalized completely. The hepatologist congratulated him—he was cured. She explained that his risk of liver cancer or cirrhosis was now minimal, though not zero. Given his F1 fibrosis, he didn't need ongoing surveillance imaging. She recommended annual liver enzyme checks through his primary care doctor and maintaining a healthy lifestyle to optimize liver health.
Specialized liver disease treatment is available through comprehensive gastroenterology practices serving diverse communities with consistent expertise and coordinated care.
Advanced hepatology services are accessible across multiple practice locations, ensuring patients can receive specialized liver care close to home. Board-certified gastroenterologists with hepatology training provide consistent diagnostic and treatment protocols regardless of location. This geographic accessibility removes barriers to specialized care for patients with chronic liver disease.
Comprehensive liver disease evaluation requires coordinated diagnostic services including advanced laboratory testing, FibroScan elastography, and imaging interpretation. Multi-location practices maintain standardized diagnostic protocols and equipment, ensuring consistent quality assessment. Patients benefit from streamlined scheduling and results coordination across the care continuum.
Hepatitis C treatment requires navigation of complex insurance authorization, specialty pharmacy networks, and patient assistance programs. Experienced coordinators familiar with multiple payer systems and pharmaceutical programs help patients access medications efficiently. This support infrastructure is consistent across practice locations, providing reliable assistance regardless of where patients receive care.
Successful Hepatitis C treatment requires consistent follow-up over several months. Multi-location practices allow patients to maintain continuity with their hepatologist while accessing convenient appointment locations. Shared electronic health records ensure all providers have complete treatment history, supporting coordinated care even if patients need to switch locations due to work or personal circumstances.
Understanding insurance coverage for Hepatitis C treatment and navigating the scheduling process helps patients access care efficiently.
Most insurance plans cover Hepatitis C screening, diagnostic testing, and treatment, though prior authorization requirements vary. Medicare and Medicaid provide comprehensive coverage for direct-acting antivirals. Commercial plans may require documentation of fibrosis stage or specialist evaluation. Specialty pharmacy coordinators assist with authorization processes and identify patient assistance programs that can reduce or eliminate out-of-pocket costs for medications.
Bring your insurance card, photo ID, and list of current medications including supplements. Gather any previous lab results, imaging reports, or medical records related to your liver health. Write down questions and symptoms you want to discuss. If you've had prior Hepatitis C testing, bring those results. Having complete information allows the hepatologist to develop a comprehensive treatment plan during your first visit.
Initial hepatology consultations typically last 45-60 minutes to allow thorough evaluation. Many practices offer online scheduling for established patients and phone scheduling for new patient appointments. When calling, mention that you're seeking evaluation for abnormal liver enzymes or Hepatitis C—this helps schedulers allocate appropriate appointment time. Ask about any pre-appointment lab work that might expedite your evaluation.
After your initial consultation, expect follow-up visits at treatment start, mid-treatment (week 4), treatment completion, and 12 weeks post-treatment for cure confirmation. Most follow-ups are brief (15-20 minutes) and can often be scheduled at convenient times. Some practices offer telehealth options for routine monitoring visits. Once cured, patients with minimal fibrosis typically transition back to primary care with no ongoing hepatology follow-up needed.
Understanding the benefits of treatment and risks of non-treatment helps patients make informed decisions about their liver health.
Modern Hepatitis C treatment offers cure rates above 95% with minimal side effects and short duration. Successful treatment eliminates the virus permanently, halts liver damage progression, reduces liver cancer risk, and often improves energy and quality of life. Treatment is straightforward: one pill daily for 8-12 weeks. The risk-benefit ratio strongly favors treatment for virtually all patients with chronic infection.
Untreated Hepatitis C causes ongoing liver inflammation that accumulates as fibrosis over years. While progression rates vary, 20-30% of patients develop cirrhosis within 20-30 years. Once cirrhosis develops, liver cancer risk increases significantly. Early treatment prevents these complications entirely. Even patients feeling well benefit from treatment—symptoms often don't appear until significant damage has occurred.
Common concerns include medication side effects, treatment cost, and time commitment. Modern direct-acting antivirals cause minimal side effects—most patients experience none. Specialty pharmacy programs and patient assistance significantly reduce costs. Treatment requires no time off work and minimal appointment burden. The hepatologist addresses individual concerns and tailors treatment to each patient's circumstances.
Achieving sustained virologic response (cure) provides lasting benefits. Liver inflammation resolves, allowing fibrosis regression in many patients. Cancer risk decreases substantially. Energy and cognitive function often improve. Patients eliminate concerns about transmitting infection to others. The peace of mind from resolving a chronic infection has significant psychological benefit. Treatment represents an investment in long-term health and quality of life.
Modern Hepatitis C treatment has evolved dramatically. Comparing current and historical approaches illustrates why today's patients have excellent outcomes.
Modern DAA regimens target specific viral proteins, achieving cure rates above 95% with 8-12 weeks of oral therapy. Treatment is well-tolerated with minimal side effects. Regimens are tailored to viral genotype and fibrosis stage. Most patients continue normal activities throughout treatment. This represents the current standard of care for all Hepatitis C patients.
Best for: All patients with chronic Hepatitis C infection, regardless of genotype or fibrosis stage
Limitations: Requires insurance authorization and specialty pharmacy coordination; medication costs are high without insurance coverage or assistance programs
Takeaway: DAA therapy has revolutionized Hepatitis C treatment, making cure accessible, tolerable, and highly effective for virtually all patients
Before 2014, Hepatitis C treatment involved weekly interferon injections plus oral ribavirin for 24-48 weeks. Cure rates ranged from 40-70% depending on genotype. Side effects were significant: flu-like symptoms, depression, anemia, and fatigue. Many patients couldn't complete treatment due to side effects. This approach is now obsolete but explains why older information about Hepatitis C treatment may sound daunting.
Best for: No longer used; included for historical context only
Limitations: Low cure rates, severe side effects, long treatment duration, and significant impact on quality of life made this approach challenging
Takeaway: Interferon-based therapy is no longer used, but its legacy explains why some patients have outdated fears about Hepatitis C treatment
Some patients consider delaying treatment to see if symptoms develop or fibrosis progresses. This approach is not recommended because ongoing viral replication causes cumulative liver damage even in asymptomatic patients. Treatment is more effective and better tolerated when initiated before advanced fibrosis develops. There is no benefit to waiting, and significant risk of disease progression.
Best for: Not recommended for any patient with confirmed chronic Hepatitis C infection
Limitations: Allows preventable liver damage accumulation, increases cirrhosis and cancer risk, and may complicate future treatment if fibrosis progresses
Takeaway: Watchful waiting is not appropriate for Hepatitis C; early treatment prevents complications and achieves better outcomes
While most Hepatitis C patients can schedule routine evaluation, certain symptoms indicate advanced liver disease requiring immediate medical attention.
Life after successful Hepatitis C treatment
Six months after his initial abnormal lab results, Caleb received confirmation of sustained virologic response—he was cured. The journey from confusion and delay to diagnosis and treatment had been shorter and easier than he'd imagined once he committed to the process.
His energy returned to levels he hadn't experienced in years. The afternoon fatigue that had become his norm disappeared. The vague abdominal discomfort resolved. He felt mentally sharper, more engaged at work and home. He hadn't realized how much the chronic infection had been affecting him until it was gone.
Caleb's hepatologist explained that his early-stage fibrosis would likely regress over time now that the inflammation had stopped. He didn't need ongoing hepatology follow-up—just annual liver enzyme checks through his primary care doctor. His liver cancer risk was now minimal. He'd prevented the progression to cirrhosis that would have been inevitable without treatment.
Looking back, Caleb wished he hadn't delayed those initial follow-up labs. But he was grateful his primary care doctor had been persistent, that the referral to hepatology had been straightforward, and that modern treatment had made cure so accessible. He now advocates for Hepatitis C screening among his friends, knowing how many people carry the virus unknowingly.
I went from confused about abnormal labs to cured of a chronic infection in less than six months. I wish I hadn't waited, but I'm grateful the treatment was so effective.
This patient journey is an educational narrative created to illustrate typical experiences with Hepatitis C diagnosis and treatment. While based on common clinical scenarios and evidence-based medical information, it represents a composite educational case rather than a specific individual's experience. Patient experiences vary based on viral genotype, fibrosis stage, insurance coverage, and individual circumstances. This content is not medical advice. Consult a board-certified gastroenterologist or hepatologist for evaluation of abnormal liver enzymes or Hepatitis C concerns specific to your situation.
Evidence-based answers to help you understand viral hepatitis diagnosis and treatment
Many Hepatitis C patients cannot identify a specific exposure event. The virus spreads through blood-to-blood contact, which can occur through medical procedures before universal screening began in 1992, tattoos or piercings from unregulated facilities, sharing personal care items like razors, or minor medical exposures. The infection often occurred decades before diagnosis, making recall difficult. What matters now is that the infection is treatable and curable regardless of how it was acquired.
Hepatitis C can be completely cured with modern direct-acting antiviral medications. Cure rates exceed 95% with 8-12 weeks of oral therapy. Sustained virologic response (undetectable virus 12 weeks after treatment completion) indicates permanent cure—the virus is eliminated from your body and will not return unless you're re-exposed. This is different from hepatitis B, which cannot be cured but can be controlled. Hepatitis C cure is achievable for virtually all patients.
Untreated Hepatitis C causes ongoing liver inflammation that accumulates as scar tissue (fibrosis) over years to decades. About 20-30% of untreated patients develop cirrhosis within 20-30 years. Once cirrhosis develops, annual liver cancer risk reaches 2-4%. Progression rates vary based on factors like alcohol use, obesity, and diabetes. Even patients feeling well should pursue treatment because symptoms often don't appear until significant damage has occurred. Treatment prevents these complications entirely.
Modern direct-acting antiviral treatment is well-tolerated with minimal side effects. Most patients experience no side effects at all. When side effects occur, they're typically mild: occasional fatigue or headache. Treatment requires no time off work and doesn't interfere with normal activities. This is dramatically different from older interferon-based therapy, which caused significant side effects. Current treatment involves one pill daily for 8-12 weeks with minimal impact on daily life.
Hepatitis C medications are expensive (often $20,000-30,000 for a treatment course), but most patients pay little to nothing out-of-pocket. Medicare, Medicaid, and commercial insurance plans cover treatment, though prior authorization is required. Specialty pharmacy coordinators help navigate insurance approval. Pharmaceutical patient assistance programs can reduce or eliminate copays for eligible patients. Financial barriers should not prevent treatment—assistance programs exist to ensure access regardless of insurance status.
Liver biopsy is rarely needed for Hepatitis C evaluation. Non-invasive tests like FibroScan (ultrasound elastography) or blood-based fibrosis markers accurately assess liver scarring without biopsy. These tests are painless, quick, and provide immediate results. Biopsy is reserved for cases where non-invasive testing is inconclusive or when other liver conditions need evaluation. Most patients complete their entire Hepatitis C evaluation and treatment without ever needing a biopsy.
Hepatitis C spreads through blood-to-blood contact, not through casual contact, sharing food, hugging, or kissing. Household transmission risk is very low. Don't share personal items that might have blood on them (razors, toothbrushes, nail clippers). Sexual transmission is uncommon in monogamous relationships but increases with multiple partners or rough sexual practices that cause bleeding. Once you're cured, you cannot transmit the virus. Family members don't need testing unless they have independent risk factors.
Family members should be tested if they have independent risk factors: blood transfusion before 1992, injection drug use, birth between 1945-1965 (baby boomer cohort), or known exposure to infected blood. Hepatitis C doesn't run in families genetically—it's an infectious disease, not an inherited condition. The CDC now recommends universal screening for all adults at least once, so family members should discuss screening with their primary care doctors regardless of your diagnosis.
True treatment failure (virus not eliminated) is rare with modern direct-acting antivirals—cure rates exceed 95%. If the virus is detected after treatment, it's usually either incomplete viral clearance (detected during treatment monitoring) or reinfection from new exposure. Incomplete clearance can be retreated with alternative regimens. Reinfection requires new exposure to infected blood. Once cured, you don't have immunity—reinfection is possible if exposed again, but this is uncommon in most patients.
Cure is confirmed by sustained virologic response testing (SVR12)—undetectable HCV RNA 12 weeks after completing treatment. Your hepatologist will check viral load during treatment (usually week 4) to confirm the medication is working, then again 12 weeks after your last dose. If the virus remains undetectable at SVR12, you're cured. This test timing is standard because late relapse after SVR12 is extremely rare. Most patients know they're cured within 5-6 months of starting treatment.
Explore additional resources to understand liver disease, digestive health, and when to seek specialized gastroenterology care.
Comprehensive information about Hepatitis C transmission, symptoms, diagnosis, and treatment options
Learn About Hepatitis C →What elevated ALT and AST levels mean and when they require further evaluation
Liver Enzyme Guide →Evidence-based strategies to protect liver health and prevent chronic liver disease
Liver Health Tips →Understanding which digestive and liver symptoms warrant specialized GI evaluation
Evaluation Guidelines →Identifying abnormal liver enzymes or Hepatitis C risk factors through screening or routine labs
Comprehensive hepatology assessment including viral load, genotype, and fibrosis staging
Understanding your specific Hepatitis C profile, treatment options, and expected outcomes
8-12 weeks of direct-acting antiviral therapy with minimal side effects and high cure rates
Mid-treatment and post-treatment viral load testing to confirm sustained virologic response
Achieving cure, preventing liver disease progression, and transitioning to routine health maintenance
Abnormal liver enzymes or Hepatitis C diagnosis can feel overwhelming, but modern treatment offers cure rates above 95% with minimal disruption to your life. Our hepatology specialists provide comprehensive evaluation, evidence-based treatment, and supportive care throughout your journey to cure.